Synthesis and the biological evaluation of 2-benzenesulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles as potential anti-hepatitis B virus agents

Antiviral Research

Volumn 71, Issue 1, 2006, Pages 7-14

  Tan, Theresa May Chin ^a   Chen, Yu ^a   Kong, Kah Hoe ^a   Bai, Jing ^a   Li, Yang ^a   Lim, Seng Gee ^a   Ang, Thiam Hong ^a   Lam, Yulin ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antiviral activity; Hepatitis B virus; Hepatitis B virus e antigen; Hepatitis B virus s antigen; Oxadiazoles

Indexed keywords

1 [2 [5 (1 BENZENESULFONYLPROPYL)[1,3,4]OXADIAZOL 2 YLSULFANYL]ETHYL] 4 (2 METHOXYPHENYL)PIPERAZINE; 1,3,4 OXADIAZOLE DERIVATIVE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; OXADIAZOLE DERIVATIVE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DETERMINATION; DRUG INHIBITION; DRUG SYNTHESIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA VIRUS; SUBSTITUTION REACTION; VIRION; VIRUS INHIBITION; VIRUS TRANSCRIPTION;

ANTIVIRAL AGENTS; DNA, VIRAL; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATOCYTES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; OXADIAZOLES; POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED;

HEPATITIS B VIRUS; RNA VIRUSES;

EID: 33745208794     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.02.007     Document Type: Article

References (41)

1. Angus P., Vaughan R., Xiong S., Yang H., Delaney W., Gibbs C., Brosgart C., Colledge D., Edwards R., Ayres A., Bartholomeusz A., and Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
2. Badger J., Minor I., Kremer M.J., Oliveira M.A., Smith T.J., Griffith J.P., Guerin D.M., Krishnaswamy S., Luo M., Rossmann M.G., McKinlay M.A., Diana G.D., Dutko F.J., Fancher M., Rueckert R.R., and Heinz B.A. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 3304-3308
3. Block T.M., Lu X., Mehta A.S., Blumberg B.S., Tennant B., Ebling M., Korba B., Lansky D.M., Jacob G.S., and Dwek R.A. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat. Med. 4 (1998) 610-614
4. Chimirri A., Grasso S., Montforte A.M., Rao A., and Zappala M. Synthesis and antitumor activity evaluation of Δ2-1,2,4-oxadiazoline derivatives. Farmaco 51 (1996) 125-129
5. Delaney IV W.E., Edwards R., Colledge D., Shaw T., Furman P., Painter G., and Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 46 (2002) 3057-3060
6. Deres K., Schroder C.H., Paessens A., Goldmann S., Hacker H.J., Weber O., Kramer T., Niewohner U., Pleiss U., Stoltefuss J., Graef E., Koletzki D., Masantschek R.N., Reimann A., Jaeger R., Gross R., Beckermann B., Schlemmer K.H., Haebich D., and Rubsamen-Waigmann H. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299 (2003) 893-896
7. Diana G.D., Volkots D.L., Nitz T.J., Bailey T.R., Long M.A., Vescio N., Aldous S., Pevear D.C., and Dutko F.J. Oxadiazoles as ester bioisosteric replacements in compounds related to disoxaril. Antirhinovirus activity. J. Med. Chem. 37 (1994) 2421-2436
8. El-Emam A.A., Al-Deeb O.A., Al-Omar M., and Lehmann J. Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12 (2004) 5107-5113
9. Fattovich G., Brollo L., Alberti A., Pontisso P., Giustina G., and Realdi G. Long-term follow-up of anti-Hbe positive chronic active hepatitis B. Hepatology 8 (1998) 1651-1654
10. Fendrick A.M. Viral respiratory infections due to rhinoviruses: current knowledge, new developments. Am. J. Ther. 10 (2003) 193-202
11. Ferenci P. Treatment of chronic viral hepatitis. Best Pract. Res. Clin. Gastroenterol. 18 Suppl. (2004) 113-120
12. Fischer K.P., Gutfreund K.S., and Tyrell D.L. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist. (2001) 118-128 (updates 4)
13. Fox M.P., Otto M.J., and McKinlay M.A. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30 (1986) 110-116
14. Fung S., Andreone P., Han S., Rajender R., Regev A., Keeffe E., Hussain M., Cursaro C., Richtmyer P., Marrero J., and Lok A. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J. Hepatol. 43 (2005) 937-943
15. King R.W., Ladner S.K., Miller T.J., Zaifert K., Perni R.B., Conway S.C., and Otto M.J. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-l-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 42 (1998) 3179-3186
16. Li Y., Wasser S., Lim S., and Tan T.M.C. Genome-wide expression profiling of RNA interference of hepatitis B virus gene expression and replication. Cell Mol. Life Sci. 61 (2004) 2113-2124
17. Lin K.W., and Kirchner J.T. Hepatitis B. Am. Fam. Phys. 69 (2004) 75-82
18. Lu X., Mehta A., Dadmarz M., Dwek R., Blumberg B.S., and Block T.M. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2380-2385
19. Luthman K., Borg S., and Hacksell U. Synthesis and use of pseudopeptides derived from 1,2,4-cxadiazole-, 1,3,4-cxadiazole- and 1,2,4-triazole-based dipeptidomimetics. Methods Mol. Med. 23 (1999) 1-23
20. Matsumoto J., Takahashi T., Agata M., Toyofuku H., and Sasada N. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor. Jpn. J. Pharmacol. 65 (1994) 51-57
21. Mehta A., Carrouee S., Conyers B., Jordan R., Butters T., Dwek R.A., and Block T.M. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology 33 (2001) 1488-1495
22. Mailliard M., and Gollan J. Emerging therapeutics for chronic hepatitis B. Annu. Rev. Med. 57 (2006) 155-166
23. Modica M., Santagati M., Guccione S., Russo F., Cagnotto A., Goegan M., and Mennini T. Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands. Eur. J. Med. Chem. 36 (2001) 287-301
24. Nakazono K., Ito Y., Wu C., and Wu G. Inhibition of hepatitis B virus replication by targeted pretreatment of complexed antisense DNA in vitro. Hepatology 23 (1996) 1297-1303
25. Nicolaides D.N., Fylaktakidou K.C., Litinas K.E., and Hadjipavlou-Litina D. Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1,2,4-oxadiazole derivatives. Eur. J. Med. Chem. 33 (1998) 715-724
26. Ocama P., Opio C.K., and Lee W. Hepatitis B virus infection: current status. Am. J. Med. 118 (2005) 1413
27. Perni R.B., Conway S.C., Ladner S.K., Zaifert K., Otto M.J., and King R.W. Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. Bioorg. Med. Chem. Lett. 10 (2000) 2687-2690
28. Pevear D.C., Fancher M.J., Felock P.J., Rossmann M.G., Miller M.S., Diana G., Treasurywala A.M., McKinlay M.A., and Dutko F.J. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J. Virol. 63 (1989) 2002-2007
29. Polański J., Jarzembek K., and Lysiak V. A search for new glucophores by isosteric replacement of carboxylic function. Acta Pol. Pharm. 58 (2000) 80-81
30. Sells M., Chen M., and Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 1005-1009
31. Shepard D.A., Heinz B.A., and Rueckert R.R. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J. Virol. 67 (1993) 2245-2254
32. Song Y., Connor D.T., Sercel A.D., Sorenson R.J., Doubleday R., Unangst P.C., Roth B.D., Beylin V.G., Gilbertsen R.B., Chan K., Schrier D.J., Guglietta A., Bornemeier D.A., and Dyer R.D. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series. J. Med. Chem. 42 (1999) 1161-1169
33. Stray S.J., Bourne C.R., Punna S., Lewis W.G., Finn M.G., and Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 8138-8143
34. Tenney D., Levine S., Rose R., Walsh A., Weinheimer S., Discotto L., Plym M., Pokornowski K., Yu C., Angus P., Ayres A., Bartholomeusz A., Sievert W., Thompson G., Warner N., Locarnini S., and Colonno R. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob. Agents Chemother. 48 (2004) 3498-3507
35. Thomas H.C. Treatment of heptatitis B viral infection. In: Zuckerman A.J. (Ed). Viral Hepatitis and Liver Disease (1998), Alan R. Liss, Inc., New York 817-822
36. Villeneuve J.P., Durantel D., Durantel S., Westland C., Xiong S., Brosgart C.L., Gibbs C.S., Parvaz P., Werle B., Trepo C., and Zoulim F. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J. Hepatol. 39 (2003) 1085-1089
37. Vu C.B., Corpuz E.G., Merry T.J., Pradeepan S.G., Bartlett C., Bohacek R.S., Botfield M.C., Eyermann C.J., Lynch B.A., MacNeil I.A., Ram M.K., van Schravendijk M.R., Violette S., and Sawyer T.K. Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70. J. Med. Chem. 42 (1999) 4088-4098
38. Weber O., Schlemmer K.H., Hartmann E., Hagelschuer I., Paessens A., Graef E., Deres K., Goldmann S., Niewoehner U., Stoltefuss J., Haebich D., Ruebsamen-Waigmann H., and Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res. 54 (2002) 69-78
39. Webster A.D. Pleconaril-an advance in the treatment of enteroviral infection in immuno-compromised patients. J. Clin. Virol. 32 (2005) 1-6
40. Ying C., de Clercq E., and Neyts J. Selective inhibitors of hepatitis B virus replication. Curr. Med. Chem. Anti-Infective Agents 2 (2003) 227-240
41. Zhang Z.F., Deng Z.B., Dong G., Liang C.J., and Peng L. Improved performance of organic light-emitting devices with 2-(4-biphenyl)-5-(4-butylphenyl)-1,3,4-oxadiazole. Displays 26 (2005) 133-136